1887

Journal of General Virology header logo

Volume 80, Issue 3

Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity Free

Abstract

Gene therapy using Fas ligand (FasL) for treatment of tumours and protection of transplant rejection is hampered because of the systemic toxicity of FasL. In the present study, recombinant replication-defective adenovirus vectors (RAds) encoding FasL under the control of either the neuronal-specific neuronal-specific enolase (NSE) promoter or the astrocyte-specific glial fibrillary acidic protein (GFAP) promoter have been constructed. The cell type-specific expression of FasL in both neurons and glial cells in primary cultures, and in neuronal and glial cell lines is demonstrated. Furthermore, transgene expression driven by the neuronal and glial promoter was not detected in fibroblastic or epithelial cell lines. Expression of FasL driven by a major immediate early human cytomegalovirus promoter (MIEhCMV) was, however, achieved in all cells tested. As a final test of the stringency of transgene-specific expression, the RAds were injected directly into the bloodstream of mice. The RAds encoding FasL under the control of the non-cell type-specific MIEhCMV promoter induced acute generalized liver haemorrhage with hepatocyte apoptosis, while the RAds containing the NSE or GFAP promoter sequences were completely non-toxic. This demonstrates the specificity of transgene expression, enhanced safety during systemic administration, and tightly regulated control of transgene expression of highly cytotoxic gene products, encoded within transcriptionally targeted RAds.

  • Received:
  • Accepted:
  • Published Online:
© Journal of General Virology 1999
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-80-3-571
1999-03-01
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/80/3/0800571a.html?itemId=/content/journal/jgv/10.1099/0022-1317-80-3-571&mimeType=html&fmt=ahah

References

  1. Allison J., Georgiou H., Strasser A., Vaux D. 1997; Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proceedings of the National Academy of Sciences, USA 94:3943–3947
     [Google Scholar]
  2. Andersen J., Garber D., Meaney C., Breakefield X. 1992; Gene transfer into mammalian central nervous system using herpes-virus vectors. Extended expression of bacterial lacZ in neurons using the neuron specific enolase promoter. Human Gene Therapy 3:487–499
     [Google Scholar]
  3. Andersen J., Frim D., Isacson O., Breakefield X. 1993; Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. Cellular and Molecular Neurobiology 13:503–515
     [Google Scholar]
  4. Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R. 1995; A role for CD95 ligand in preventing graft rejection. Nature 377:630–632
     [Google Scholar]
  5. Bonetti B., Pohl J., Gao Y., Raine C. 1997; Cell death during autoimmune demyelination: effector but not target cells are eliminated by apoptosis. Journal of Immunology 159:5733–5741
     [Google Scholar]
  6. Boyd J., Malstrom S., Subramanian T., Venkatesh L., Schaeper U., Elangovan B., Dsaeipper C., Chinnadurai G. 1994; Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins. Cell 79:341–351
     [Google Scholar]
  7. Brenner M., Kisseberth W., Su Y., Besnard F., Messing A. 1994; GFAP promoter directs astrocyte-specific expression in transgenic mice. Journal of Neuroscience 14:1030–1037
     [Google Scholar]
  8. Byrnes A., MacLaren R., Charlton H. 1996; Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression and demyelination. Journal of Neuroscience 16:3045–3055
     [Google Scholar]
  9. Castro M. G., Goya R. G., Sosa Y. E., Rowe J., Larregina A., Morelli A., Lowenstein P. R. 1997; Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: long term expression, cell cycle dependency, and effects on hormone secretion. Endocrinology 138:2184–2194
     [Google Scholar]
  10. Forss-Peter S., Danielson P., Catsicas S., Battenberg E., Price J., Hurenberg M., Sutcliffe J. 1990; Transgenic mice expressing β-galactosidase in mature neurons under neuron specific enolase promoter control. Neuron 5:187–197
     [Google Scholar]
  11. French L., Hahne M., Viard I., Radlgruber G., Zanone R., Becker K., Muller Ch., Tschopp J. 1996; Fas and fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. Journal of Cell Biology 133:335–343
     [Google Scholar]
  12. Galle P., Hofmann W., Walczak H., Schaller H., Otto G., Stremmel W., Krammer P., Runkel L. 1995; Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. Journal of Experimental Medicine 182:1223–1230
     [Google Scholar]
  13. Geddes B., Harding T., Hughes D., Byrnes A., Lightman S., Conde G., Uney J. 1996; Persistent transgene expression in the hypo-thalamus following extereotaxic delivery of a recombinant adenovirus-suppression on the immune response with cyclosporine. Endocrinology 137:5166–5169
     [Google Scholar]
  14. Geddes B., Harding T., Lightman S., Uney J. 1997; Long-term gene therapy in the CNS: reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin. Nature Medicine 3:1402–1404
     [Google Scholar]
  15. Green D., Ware C. 1997; Fas-ligand: privilege and peril. Proceedings of the National Academy of Sciences, USA 94:5986–5990
     [Google Scholar]
  16. Griffith T., Ferguson T. 1997; The role of FasL-induced apoptosis in immune privilege. Immunology Today 18:240–244
     [Google Scholar]
  17. Griffith T., Brunner T., Fletcher S., Green D., Ferguson T. 1996; Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189–1192
     [Google Scholar]
  18. Hahne M., Rimoldi D., Schrotter M., Romero P., Schreier M., French L., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J. C., Tschopp J. 1996; Melanoma cell expression of Fas (APO-1/CD95) ligand: implications for tumour immune escape. Science 274:1363–1366
     [Google Scholar]
  19. Hashimoto M., Aruga J., Hosoya Y., Kenegae Y., Saito I., Mikoshiba K. 1996; A neural cell-type-specific expression system using recombinant adenovirus vectors. Human Gene Therapy 7:149–158
     [Google Scholar]
  20. Hoffman M., Zheng C., Baum B., O’Connell B., Kleinman H. 1997; Identification of components in Matrigel involved in salivary gland acinar cell differentiation using an adenovirus vector with an acinar cell specific promoter luciferase reporter. Matrix Biology 16:72
     [Google Scholar]
  21. Imler J., Dupuit F., Charteir C., Accart N., Dieterle A., Schultz H., Fuchelle E., Pavirani A. 1996; Targeting cell-specific gene-expression with an adenovirus vector containing the lac Z gene under the control of the CFTR promoter. Gene Therapy 3:49–58
     [Google Scholar]
  22. Kajiwara K., Byrnes A., Charlton H., Wood M., Wood K. 1997; Immune responses to adenoviral vectors during gene transfer in the brain. Human Gene Therapy 8:243–265
     [Google Scholar]
  23. Kanai F., Shiratori Y., Yoshida Y., Wakimoto H., Hamada H., Kanegae Y., Saito I., Nakabayashi H., Tamaoki T., Tanaka T., Lan K., Kato N., Shina S. 1996; Gene-therapy for alpha-fetoprotein producing human hepatoma cells by adenovirus-mediated transfer of the herpes-simplex virus thymidine kinase gene. Hepatology 23:1359–1368
     [Google Scholar]
  24. Kang A., Schneider D., Lin Z., Hanahan D., Dicher D., Stock P., Baekkekov S. 1997; Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Medicine 3:738–743
     [Google Scholar]
  25. Kaplitt M. G., Kwong A. D., Kleopoulos S. P., Mobbs C. V., Rabkin S. D., Pfaff D. W. 1994; Preproenkephalin promoter yields region-specific and long term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proceedings of the National Academy of Sciences, USA 91:8979–8983
     [Google Scholar]
  26. Kay M., Meuse L., Gown A., Linsley P., Hollenbaugh D., Aruffo A., Ochs H., Wilson C. 1997; Transient immunomodulation with anti-CD40 ligand antibody and CTLA4 Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proceedings of the National Academy of Sciences, USA 94:4686–4691
     [Google Scholar]
  27. Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. 1995; Metalloproteinase-mediated release of human Fas ligand. Journal of Experimental Medicine 182:1777–1783
     [Google Scholar]
  28. Kiener P., Davis P., Starling G., Mehlin C., Klebanoff S., Ledbetter J., Liles W. 1997; Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. Journal of Experimental Medicine 185:1511–1516
     [Google Scholar]
  29. Kim S., Lin H., Barr E., Chu L., Leiden J., Parmack M. 1997; Transcriptional targeting of replication–defective adenovirus transgene expression to smooth muscle cells in vivo. Journal of Clinical Investigation 100:1006–1014
     [Google Scholar]
  30. Ko S., Cheon J., Kao C., Gotoh A., Shirakawa T., Sikes R., Karsenty G., Chung L. 1996; Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Research 56:4614–4619
     [Google Scholar]
  31. Koppi T., Toughbement T., Lewinsohn D., Lynch D., Alderson M. 1997; CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-derived dendritic cells. European Journal of Immunology 27:3161–3165
     [Google Scholar]
  32. Korbutt G., Elliott J., Rajotte R. 1997; Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows longterm graft survival without systemic immunosuppression. Diabetes 46:317–322
     [Google Scholar]
  33. Lan K., Kanai F., Shiratori Y., Ohashi M., Tanaka T., Okudaira T., Yoshida Y., Hamada H., Omata M. 1997; In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Research 57:4279–4284
     [Google Scholar]
  34. Larregina A., Morelli A., Dewey R., Castro M., Fontana A., Lowenstein P. 1998; FasL induces Fas/Apo1-mediated apoptosis in human embryonic kidney 293 cells routinely used to generate E1–deleted adenoviral vectors. Gene Therapy 5:563–568
     [Google Scholar]
  35. Lau H., Yu M., Fontana A., Stoeckert Ch. 1996; Prevention of islets allograft rejection with engineered myoblast expressing FasL in mice. Science 273:109–112
     [Google Scholar]
  36. Lin R., Matesic D. 1994; Immunohistochemical demonstration of neuron-specific enolase and microtubule-associated protein 2 in reactive astrocytes after injury in the adult forebrain. Neuroscience 60:11–16
     [Google Scholar]
  37. Lowenstein P. R., Morrison E. E., Bain D., Shering A. F., Banting G., Douglas P., Castro M. G. 1994; Polarized distribution of the trans-Golgi network marker TGN38 during the in vitro development of neocortical neurons: effects of nocodazole and brefeldin A. European Journal of Neuroscience 6:1453–1465
     [Google Scholar]
  38. Lowenstein P. R., Shering A. F., Morrison E., Tomasec P., Bain D., Jacob T. J. C., Wu J., Prescott A., Castro M. G. 1995; Synapto-genesis and distribution of presynaptic axonal varicosities in low density primary cultures of neocortex: an immunocytochemical study utilizing synaptic vesicle-specific antibodies, and an electrophysiological examination utilizing whole cell recording. Journal of Neurocytology 24:301–317
     [Google Scholar]
  39. Malipiero U., Frei K., Spanaus K., Agresti C., Lassmann H., Hahne M., Tschopp J., Eugster H., Fontana A. 1997; Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice. European Journal ofImmunology 12:3151–3160
     [Google Scholar]
  40. Miura M., Tamura T., Mikoshiba K. 1990; Cell-specific expression of the mouse glial fibrillary acidic protein gene: identification of the cis- and trans-acting promoter elements for astrocyte–specific expression. Journal of Neurochemistry 55:1180–1188
     [Google Scholar]
  41. Morishita K., Johnson D., Williams L. 1995; A novel promoter for vascular endothelial growth-factor receptor (flt-1) that confers endothelial-specific gene-expression. Journal of Biological Chemistry 270:27948–27953
     [Google Scholar]
  42. Muruve D., Nicolson A., Manfro R., Strom T., Sukhatme V., Libermann T. 1997; Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Human Gene Therapy 8:955–963
     [Google Scholar]
  43. Nicoletti I., Migliorati G., Pagliacci M., Grignani F., Riccardi C. 1991; A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. Journal of Immunological Methods 139:271–279
     [Google Scholar]
  44. Niehans G., Brunner T., Frizelle S. P., Liston J., Salerno C. T., Knapp D. J., Green D. R., Kratzke R. A. 1997; Human lung carcinoma express Fas ligand. Cancer Research 57:1007–1012
     [Google Scholar]
  45. Nishimura T., Akiyama H., Yonehara S., Kondo H., Ikeda K., Kato M., Iseki E., Kosaka K. 1995; Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Research 695:137–145
     [Google Scholar]
  46. O’Connell J., O’Sullivan G., Collings J., Shanahan F. 1996; The Fas counterattack: Fas-mediated T cell killing by colon cancer expressing Fas ligand. Journal of Experimental Medicine 184:1075–1082
     [Google Scholar]
  47. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., Nagata S. 1993; Lethal effect of the anti-fas antibody in mice. Nature 364:806–809
     [Google Scholar]
  48. Osborne B. A. 1996; Apoptosis and the maintenance of homeostasis in the immune system. Current Opinion in Immunology 8:245–254
     [Google Scholar]
  49. Peel A., Zolotukhin S., Schrimsher G., Muzyczka N., Reier P. 1997; Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Therapy 4:16–24
     [Google Scholar]
  50. Rensing-Ehl A., Rei K., Flury R., Matiba B., Mariani S., Weller M., Aebischer P., Krammer P., Fontana A. 1995; Local Apo-1/Fas (CD95) ligand-mediated tumor cell killing in vivo . European Journal of Immunology 25:2253–2258
     [Google Scholar]
  51. Rensing-Ehl A., Malipiero U., Irmler M., Tschopp J., Constam D., Fontana A. 1996; Neurons induced to express major histocompatibility complex class I antigen are killed via the perforin and not the Fas (APO-1/CD95) pathway. European Journal of Immunology 26:2271–2274
     [Google Scholar]
  52. Rodriguez R., Schuur E., Lim H., Henderson G., Simons J., Henderson D. 1997; Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Research 13:1559–1563
     [Google Scholar]
  53. Roemer K., Johnson P., Friedmann T. 1995; Transduction of foreign regulatory sequences by a replication-defective herpes simplex virus type 1: the rat neuron-specific enolase promoter. Virus Research 35:781–789
     [Google Scholar]
  54. Rothmann T., Katus H., Hartong R., Perricaudet M., Franz W. 1996; Heart muscle-specific gene-expression using replication-defective recombinant adenovirus. Gene Therapy 3:919–926
     [Google Scholar]
  55. Saas P., Walker P. R., Hahne M., Quiquerez A. L., Schnuriger V., Perrin G., French L., Van Meir E. G., de Tribolet N., Tschopp J., Dietrich P. Y. 1997; Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?. Journal of Clinical Investigation 99:1173–1178
     [Google Scholar]
  56. Samaniego L., Wu N., DeLuca N. 1997; The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected–cell survival in the absence of ICP4 and ICP27. Journal of Virology 71:4614–4625
     [Google Scholar]
  57. Samaniego L., Neiderhiser L., DeLuca N. 1998; Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. Journal of Virology 72:3307–3320
     [Google Scholar]
  58. Sanberg P., Borlongan C., Saporta S., Cameron D. 1996; Testis-derived sertoli cells survive and provide localized immunoprotection for xenografts in rat brain. Nature Biotechnology 14:1692–1695
     [Google Scholar]
  59. Sandig V., Loser P., Lieber A., Kay M., Strauss M. 1996; HBV-derived promoters direct liver-specific expression of an adenovirally transduced LDL receptor gene. Gene Therapy 3:1002–1009
     [Google Scholar]
  60. Sata M., Perlman H., Muruve D. A., Silver M., Ikebe M., Libermann T. A., Oettgen P., Walsh K. 1998; Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proceedings of the National Academy of Sciences, USA 95:1213–1217
     [Google Scholar]
  61. Schneider P., Holler N., Bodmer J., Hahna M., Frei K., Fontana A., Tschopp J. 1998; Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with down regulation of its proapoptotic activity and loss of liver toxicity. Journal of Experimental Medicine 187:1205–1213
     [Google Scholar]
  62. Seino K., Kayagaki N., Okumura K., Yagita H. 1997; Antitumor effect of locally produced CD95 ligand. Nature Medicine 3:165–170
     [Google Scholar]
  63. Shering A. F., Bain D., Stewart K., Epstein A. L., Castro M. G., Wilkinson G. W. G., Lowenstein P. R. 1997; Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. Journal of General Virology 78:445–459
     [Google Scholar]
  64. Shimizu M., Yoshimoto T., Nagata S., Matsuzawa A. 1996; A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo . Biochemical and Biophysical Research Communication 228:375–379
     [Google Scholar]
  65. Siders W., Halloran P., Fenton R. 1996; Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Research 56:5638–5646
     [Google Scholar]
  66. Strand S., Hoffmann W., Hug H., Muller M., Otto G., Strand D., Mariani S., Stremmel W., Krammer P., Galle P. 1996; Lymphocyte apoptosis induced by CD95 (APO-1/FAS) ligand: implications for tumour immune escape. Nature Medicine 2:1361–1366
     [Google Scholar]
  67. Suda T., Nagata S. 1994; Purification and characterization of the Fas-ligand that induces apoptosis. Journal of Experimental Medicine 179:873–879
     [Google Scholar]
  68. Suda T., Takahashi T., Golstein P., Nagata S. 1993; Molecular cloning and expression of the FAS ligand, a novel member of tumour necrosis factor family. Cell 75:1169–1178
     [Google Scholar]
  69. Tollefson A. E., Hermiston T. W., Lichtenstein D. L., Colle C. F., Tripp R. A., Dimitrov T., Toth K., Wells C. E., Doherty P. C., Wold W. S. M. 1998; Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 392:726–730
     [Google Scholar]
  70. van Parijs L., Abbas A. 1996; Role of Fas-mediated cell death in the regulation of immune responses. Current Opinion in Immunology 8:355–361
     [Google Scholar]
  71. Vaux D. 1995; Ways around rejection. Nature 377:576–577
     [Google Scholar]
  72. Weller M., Frei K., Groscurth P., Krammer P. H., Yonekawa Y., Fontana A. 1994; Anti-Fas Apo-1 antibody mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. Journal of Clinical Investigation 94:954–964
     [Google Scholar]
  73. Wilkinson G. W. G., Akrigg A. 1991; Constitutive and enhanced expression from the CMV major IE-promoter in a defective adenovirus vector. Nucleic Acids Research 20:2233–2239
     [Google Scholar]
  74. Wrann M., Bodmer S., Demartin R., Siepl C., Hoferwarbinek R., Frei K., Hofer E., Fontana A. 1987; T-cell supressor factor from human glioblastoma cells is a 12*5 kD protein closely related to transforming growth factor beta. EMBO Journal 6:1633–1636
     [Google Scholar]
  75. Zhang H., Yang Y., Horton J., Samoilova E., Judge T., Turka L., Wilson J., Chen Y. 1997; Amelioration of collagen-induced arthritis by CD95 (Apo-1 /Fas)-ligand gene transfer. Journal of Clinical Investigation 100:1951–1957
     [Google Scholar]
  76. Zhang H., Bilbao G., Zhou T., Contreras J., Gomez-Navarro J., Feng M., Saito I., Mountz J., Curiel D. 1998; Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression. Journal of Virology 72:2483–2490
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-80-3-571
Loading
Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity
J. Gen. Virol. 80, 571 (1999); https://doi.org/10.1099/0022-1317-80-3-571
/content/journal/jgv/10.1099/0022-1317-80-3-571
/content/journal/jgv/10.1099/0022-1317-80-3-571
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error